We serve as both consultant and multiple grantee of the Gates Foundation, focusing on issues relating to medication adherence and differentiated care in Tuberculosis and HIV/AIDS in India, China, and Africa.
The Gates Foundation understood that TB medication adherence is essential for positive treatment outcomes, but little was known about baseline adherence rates, drivers of poor adherence and potential adherence-enhancing interventions, particularly in resource limited settings.
Using structured, insights-oriented interviews with patients, providers, disease state experts, and other key stakeholders, we assembled a practical and actionable set of findings, which served as critical inputs into the adherence elements of the Gates Foundation’s comprehensive strategy to modernize TB delivery.
Directly Observed Therapy (DOT), the established standard of care for TB patient management, is burdensome for patients and negatively impacts retention in care. Alternative adherence monitoring technologies were prohibitively expensive and were inappropriate for TB medication format and supply chains.
We served as global project lead for the development, manufacture, testing, and deployment at scale of a highly accurate, highly affordable, TB blister-compatible medication adherence technology to improve patient medication adherence and to enable and inform differentiated care.
We are advisers to Novartis’ global initiative, The Digital Acceleration Lab. In this capacity, we help (i) identify unmet patient and health system needs on a disease state specific basis, and (ii) identify technologies or digital solutions that can address these needs, enhance patient care, and improve health outcomes.
We serve as advisers to the Virginia Commonwealth University School of Engineering’s Medicines For All Institute, a Bill & Melinda Gates-funded initiative to transform pharmaceutical manufacturing processes to reduce raw material costs and, thereby, improve patient access to life saving global health medications.
Medicines for All
The VCU School of Engineering’s Medicines For All Institute successfully demonstrated its ability to optimize manufacturing processes to reduce the cost of global health medications. M4ALL was seeking additional support from the Gates Foundation to dramatically scale up its capabilities and capacity to further positively impact patient access.
The Arcady Group supported M4ALL in its efforts to dramatically expand its capabilities and capacity. Specifically, we assisted in the development of a detailed business plan and grant proposal for the scale-up of M4ALL. In addition, The Arcady Group helped M4ALL access and engage with global health organizations and generic manufacturers who may be willing sponsors for M4ALL optimization projects.. As a result of these efforts, M4ALL is expected to receive the requested funding and will begin scaling up in the late 2017